Document is current
Any future updates will be listed below
-
Authors
Abreu-Mota, Tiago https://orcid.org/0000-0002-0891-4734
Marx, Anna-Friederike
Winterberg, Dorothee https://orcid.org/0009-0009-9840-8074
Tintignac, Karen
Fixemer, Jonas
Geier, Florian
Brodmann, Nicole
Seven, Cemre
Reichmuth, Claudia https://orcid.org/0009-0009-1674-6839
Kastner, Anna Lena https://orcid.org/0009-0003-3726-3306
Lu, Min
Bonilla, Weldy V.
Dimitrova, Mirela
Sahin, Mehmet
Zimmer, Gert https://orcid.org/0000-0002-2708-2507
Peipp, Matthias
Pinschewer, Daniel D. https://orcid.org/0000-0002-1594-3189
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_215043)
- License Information
-
More Information
Article History
Received: 28 May 2025
Accepted: 17 March 2026
First Online: 6 April 2026
Competing interests
: D.D.P. is a founder, consultant and shareholder of Hookipa Pharma Inc. commercializing arenavirus-based vector technology, and he as well as W.V.B. are listed as inventor on corresponding patents. The remaining authors declare no competing interests.
